Gynecologic Cancers

Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.

Neoadjuvant pembrolizumab elicited high clinical activity in patients with mismatch repair deficiency/microsatellite instability high solid tumors and was well tolerated.

January is cervical cancer awareness month. This fourth article in a series underscores the role of the nurse or social workers in patient advocacy.

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.

The panel shares the most critical unmet needs for patients with endometrial cancer.

An analysis of 141 children who had prenatal exposure to maternal cancer showed promising cognitive and behavioral functions at age 9 years.

January is cervical cancer awareness month. This third article in a series highlights current cervical cancer treatment options.

Kimberly A. Spickes, CNP, discusses how often patients with endometrial cancer have dose reductions or interruptions at her institution, and who is involved in the decision to dose-reduce.

Nurse Practitioner Kimberly Halla explains the proactive measures she takes to ensure patients with endometrial cancer are prepared to experience and manage the adverse effects of treatment.

January is cervical cancer awareness month. This second article in a series highlights current cervical screening guidelines.

Patients with heavily pretreated, platinum-resistant ovarian cancer showed promising responses with a triplet regimen consisting of COM701, BMS-986207, and nivolumab.

Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.

Kimberly Halla, NP, describes the standards for monitoring patients on therapy for recurrent endometrial cancer, including how often patients are seen in-person.

The panel explains how to educate patients on the adverse effects they may experience with chemotherapy, their options for management, and the importance of encouraging patients to contact their care team.

The panel reviews the second-line treatment options for patients with recurrent endometrial cancer.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

Maintenance therapy with rucaparib monotherapy improved progression-free survival compared with placebo. However, the treatment also significantly elevated anemia and neutropenia rates in this setting.

Nurse Practitioner Kathleen Lutz talks about the efficacy of chemotherapy in patients with endometrial cancer, and how she discusses the chance of disease recurrence with patients.

Continuing her discussion, Kathleen highlights the most common adverse events she sees in patients treated with chemotherapy for advanced endometrial cancer who are unfit for surgery.

Kathleen Lutz, RN, NP-BC WH, explains the most commonly used first-line treatment options in patients with advanced endometrial cancer who are unsuitable candidates for surgery.

The panel reviews the current treatment modalities for endometrial cancer and in what circumstances each is considered for a patient.

Lenvatinib is approved in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer who have disease progression after systemic therapy, are not candidates for curative surgery or radiation, and who are mismatch repair proficient or not microsatellite instability–high.

Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, met a predetermined progression-free survival end point in the phase 3 RUBY trial.

The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.

Kathleen Lutz, RN, NP-BC WH, presents a 76-year-old woman with advanced endometrial cancer, and the panel assesses the chosen treatment regimens.